Cationic polyamidoamine dendrimers as modulators of EGFR signaling in vitro and in vivo

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Akhtar, Saghir ^a   Al Zaid, Bashayer ^a   El Hashim, Ahmed Z ^a   Chandrasekhar, Bindu ^a   Attur, Sreeja ^a   Yousif, Mariam H M ^a   Benter, Ibrahim F ^a,b   Chai, Karl X ^c  

^a KUWAIT UNIVERSITY   (Kuwait)

^b EASTERN MEDITERRANEAN UNIVERSITY   (Turkey)

^c UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; APOCYNIN; CATALASE; DENDRIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYAMIDOAMINE; TEMPOL; PAMAM STARBURST; POLYAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; KIDNEY; METABOLISM; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; DENDRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; IN VITRO TECHNIQUES; KIDNEY; MALE; MAP KINASE SIGNALING SYSTEM; POLYAMINES; RATS; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84940560613     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132215     Document Type: Article

References (70)

1. Duncan R, Izzo L. Dendrimerbiocompatibility and toxicity. Adv. Drug Deliv. 2005; 57: 2215-2237.
2. Labieniec-Watala M, Watala C. PAMAM dendrimers: destined for success or doomed to fail? Plain and modified PAMAM dendrimers in the context of biomedical applications. J Pharm Sci. 2015; 104(1): 2-14. doi: 10.1002/jps.24222 PMID: 25363074
3. Pettit MW, Griffiths P, Ferruti P, Richardson SC. Poly(amidoamine) polymers: soluble linear amphiphilic drug-delivery systems for genes, proteins and oligonucleotides. Ther. Deliv. 2011; 2: 907-917. PMID: 22833902
4. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans. 2007; 35: 61-67. PMID: 17233602
5. Shakhbazau A, Isayenka I, Kartel N, Goncharova N, Seviaryn I, Kosmacheva S. Transfection efficiencies of PAMAM dendrimers correlate inversely with their hydrophobicity. Int J Pharm. 2010; 383: 228-235. doi: 10.1016/j.ijpharm.2009.09.020 PMID: 19770028
6. Tang MX, Szoka FC. The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther. 1997; 4: 823-832. PMID: 9338011
7. Tang MX, Redemann CT, Szoka FC Jr. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug. Chem. 1996; 7: 703-714. PMID: 8950489
8. Luo K, He B, Wu Y, Shen Y, Gu Z. Functional and biodegradable dendritic macromolecules with controlled architectures as nontoxic and efficient nanoscale gene vectors. Biotechnol Adv. 2014; 32(4): 818-830. doi: 10.1016/j.biotechadv.2013.12.008 PMID: 24389086
9. Hong S, Leroueil PR, Janus EK, Peters JL, Kober MM, Islam MT, et al. Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem. 2006; 17(3): 728-734. PMID: 16704211
10. Sadekar S, Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: Implications for oral drug delivery. Adv. Drug Deliv. 2012; 64: 571-588.
11. Conti DS, Brewer D, Grashik J, Avasarala S, da Rocha SR. Poly(amidoamine)dendrimernanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol Pharm. 2014; 11(6): 1808-1822. doi: 10.1021/mp4006358 PMID: 24811243
12. Shcharbin D, Shakhbazau A, Bryszewska M. Poly(amidoamine) dendrimer complexes as a platform for gene delivery. Expert Opin Drug Deliv. 2013; 10(12): 1687-1698. doi: 10.1517/17425247.2013.853661 PMID: 24168461
13. Zhang Y, Zhou C, Kwak KJ, Wang X, Yung B, Lee LJ, et al. Efficient siRNA delivery using a polyamidoamine dendrimer with a modified pentaerythritol core. Pharm Res. 2012; 29:1627-1636. doi: 10.1007/s11095-012-0676-x PMID: 22274556
14. Movassaghian S, Moghimi HR, Shirazi FH, Torchilin VP. Dendrosome-dendriplex inside liposomes: as a gene delivery system. J. Drug Target. 2011; 19: 925-932. doi: 10.3109/1061186X.2011.628396 PMID: 22023509
15. Akhtar S. Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics. Expert Opin Drug Metab Toxicol. 2010; 6:1347-1362. doi: 10.1517/17425255.2010.518611 PMID: 20929276
16. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 2007a; 117: 3623-3632.
17. Akhtar S, Benter IF. Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. 2007b; 59:164-182.
18. Hollins AJ, Omidi Y, Benter IF, Akhtar S. Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J. Drug Target. 2007; 15: 83-88. PMID: 17365277
19. Akhtar S. Non-viral cancer gene therapy: beyond delivery. Gene Ther. 2006; 13(9): 739-740. PMID: 18360944
20. Tang Y, Han Y, Liu L, Shen W, Zhang H, Wang Y, et al. Protective effects and mechanisms of G5 PAMAM dendrimers against acute pancreatitis induced by caerulein in mice. Biomacromolecules. 2015; 16(1): 174-182. doi: 10.1021/bm501390d PMID: 25479110
21. Nyitrai G, Keszthelyi T, Bóta A, Simon A, Töke O, Horváth G, et al. Sodium selective ion channel formation in living cell membranes by polyamidoamine dendrimer. Biochim Biophys Acta. 2013; 1828(8): 1873-1880. doi: 10.1016/j.bbamem.2013.04.004 PMID: 23597947
22. Labieniec-Watala M, Przygodzki T, Sebekova K, Watala C. Can metabolic impairments in experimental diabetes be cured with poly(amido)amine (PAMAM) G4 dendrimers? In the search for minimizing of the adverse effects of PAMAM administration. Int J Pharm. 2014; 464(1-2): 152-167. doi: 10.1016/j.ijpharm.2014.01.011 PMID: 24463003
23. Labieniec M, Watala C. Use of poly(amido)amine dendrimers in prevention of early non-enzymatic modifications of biomacromolecules. Biochimie. 2010; 92:1296-1305. doi: 10.1016/j.biochi.2010.06.002 PMID: 20542077
24. Labieniec M, Ulicna O, Vancova O, Glowacki R, Sebekova K, Bald E, et al. PAMAM G4 dendrimers lower high glucose but do not improve reduced survival in diabetic rats. Int. J. Pharm. 2008; 364:142-149. doi: 10.1016/j.ijpharm.2008.08.001 PMID: 18761397
25. Förstner P, Bayer F, Kalu N, Felsen S, Förtsch C, Aloufi A, et al. Cationic PAMAM dendrimers as pore-blocking binary toxin inhibitors. Biomacromolecules. 2014; 15(7): 2461-2474. doi: 10.1021/bm500328v PMID: 24954629
26. Durán-Lara E, Guzmán L, John A, Fuentes E, Alarcón M, Palomo I, et al. PAMAM dendrimer derivatives as a potential drug for antithrombotic therapy. Eur J Med Chem. 2013; 69: 601-608. doi: 10.1016/j.ejmech.2013.08.047 PMID: 24095753
27. Jain S, Pitoc GA, Holl EK, Zhang Y, Borst L, Leong KW, et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc. Natl. Acad. Sci. 2012; 109:12938-12943. doi: 10.1073/pnas.1204928109 PMID: 22837404
28. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014; 79: 34-74. doi: 10.1016/j.phrs.2013.11.002 PMID: 24269963
29. Dhomen NS, Mariadason J, Tebbutt N, Scott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit RevOncog. 2012; 17: 31-50. PMID: 22471663
30. Juliano RL, Carver K, Cao C, Ming X. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. J Drug Target. 2012; 21(1): 27-43.
31. Endres NF, Barros T, Cantor AJ, Kuriyan J. Emerging concepts in the regulation of the EGF receptor and other receptor tyrosine kinases. Trends Biochem Sci. 2014; 39(10):437-446. doi: 10.1016/j.tibs.2014.08.001 PMID: 25242369
32. Siddiqui S, Fang M, Ni B, Lu D, Martin B, Maudsley S. Central role of the EGF receptor in neurometabolic aging. Int. J. Endocrinol. 2012; 2012: 739428. doi: 10.1155/2012/739428 PMID: 22754566
33. Akhtar S, Yousif MH, Dhaunsi GS, Sarkhouh F, Chandrasekhar B, Attur S et al. Activation of ErbB2 and Downstream Signaling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction. PLoSOne. 2013a; 8: e67813.
34. Akhtar S, Yousif MH, Chandrasekhar B, Benter IF. Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PLoSOne. 2012a; 7(6): e39066.
35. Akhtar S, Yousif MH, Dhaunsi GS, Chandrasekhar B, Al-Farsi O, Benter IF. Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol. 2012b; 165:1390-1400.
36. Akhtar S, Chandrasekhar B, Attur S, Yousif MH, Benter IF. On the nanotoxicity of PAMAM dendrimers: Superfect stimulates the EGFR-ERK1/2 signal transduction pathway via an oxidative stress-dependent mechanism in HEK 293 cells. Int J Pharm. 2013b; 448(1): 239-246.
37. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtar S. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J. Drug Target. 2003; 11: 311-323. PMID: 14668052
38. Chauhan AS, Diwan PV, Jain NK, Tomalia DA. Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers. Biomacromolecules. 2009; 10:1195-1202. doi: 10.1021/bm9000298 PMID: 19348417
39. Li Y, Zeng X, Wang S, Sun Y, Wang Z, Fan J, Song P, et al. Inhibition of autophagy protects against PAMAM dendrimers-induced hepatotoxicity. Nanotoxicology. 2014;1-12. [Epub ahead of print] PMID: 24983897.
40. Benter IF, Canatan H, Benboubetra M, Yousif MH, Akhtar S. Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis. Vascul Pharmacol. 2009; 51 (2-3): 101-109. doi: 10.1016/j.vph.2009.04.004 PMID: 19410658
41. Zhang MZ, Wang Y, Paueksakon P, Harris RC. Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes. 2014; 63(6): 2063-2072. doi: 10.2337/db13-1279 PMID: 24705402
42. Advani A, Wiggins KJ, Cox AJ, Zhang Y, Gilbert RE, Kelly DJ. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology (Carlton). 2011; 16(6): 573-581.
43. Shcharbin D, Janaszewska A, Klajnert-Maculewicz B, Ziemba B, Dzmitruk V, Halets I. How to study dendrimers and dendriplexes III. Biodistribution, pharmacokinetics and toxicity in vivo. J Control Release. 2014; 181: 40-52. doi: 10.1016/j.jconrel.2014.02.021 PMID: 24607663
44. Sadekar S, Ray A, Janàt-Amsbury M, Peterson CM, Ghandehari H. Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice. Biomacromolecules. 2011; 12(1): 88-96.
45. Erratum in: Biomacromolecules. 2011;12(9): 3351. doi: 10.1021/bm101046d PMID: 21128624
46. Alaoui-Jamali MA, Morand GB, da Silva SD. ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics. Front Genet. 2015; 4(6): 17.
47. Price KA, Cohen EE. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Oral Oncol. 2015; 51(5): 399-408. doi: 10.1016/j.oraloncology.2015.01.018 PMID: 25725588
48. Han J, Shuvaev VV, Muzykantov VR. Targeted interception of signaling reactive oxygen species in the vascular endothelium. Ther. Deliv. 2012; 3: 263-276. PMID: 22834201
49. Wilcox CS. Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther. 2010; 126:119-145. doi: 10.1016/j.pharmthera.2010.01.003 PMID: 20153367
50. Sur S, Agrawal DK. Transactivation of EGFR by G protein-coupled receptor in the pathophysiology of intimal hyperplasia. CurrVasc Pharmacol. 2014; 12(2):190-201. PMID: 24568153
51. Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor. Annu Rev Biochem. 2015 [Epub ahead of print] PMID: 25621509.
52. Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, Wemmer DE, et al. Architecture and membrane interactions of the EGF receptor. Cell. 2013; 152(3): 557-569. doi: 10.1016/j.cell.2012.12.030 PMID: 23374350
53. Lemmon MA, Schlessinger J, Ferguson KM. The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harb Perspect Biol. 2014; 6(4): a020768. doi: 10.1101/cshperspect.a020768 PMID: 24691965
54. Avaritt BR, Swaan PW. Intracellular Ca2+ release mediates cationic but not anionic poly(amidoamine) (PAMAM) dendrimer-induced tight junction modulation. Pharm Res. 2014; 31(9): 2429-2438. doi: 10.1007/s11095-014-1338-y PMID: 24648136
55. Lill NL, Sever NI. Where EGF receptors transmit their signals. Sci Signal. 2012; 5: pe41. PMID: 23012653
56. Omerovic J, Hammond D E, Prior IA. Clague MJ. Global Snapshot of the Influence of Endocytosis upon EGF Receptor Signaling Output. J. Proteome. Res. 2012; 11: 5157-5166. doi: 10.1021/pr3007304 PMID: 22974187
57. Albertazzi L, Serresi M, Albanese A, Beltram F. Dendrimer internalization and intracellular trafficking in living cells. Mol. Pharm. 2010; 7: 680-688. doi: 10.1021/mp9002464 PMID: 20394437
58. Seib FP, Jones AT, Duncan R. Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimersin B16f10 melanoma cells. J Control Release. 2007; 117: 291-300. PMID: 17210200
59. Cui J, Hu YF, Feng XM, Tian T, Guo YH, Ma JW, et al. EGFR inhibitors and autophagy in cancer treatment. Tumour Biol. 2014; 35(12): 11701-11709. doi: 10.1007/s13277-014-2660-z PMID: 25293518
60. Lee JH, Cha KE, Kim MS, Hong HW, Chung DJ, Ryu G, et al. Nanosized polyamidoamine (PAMAM) dendrimer-induced apoptosis mediated by mitochondrial dysfunction. Toxicol. Lett. 2009; 190: 202-207. doi: 10.1016/j.toxlet.2009.07.018 PMID: 19643170
61. Mukherjee SP, Davoren M, Byrne HJ. In vitro mammalian cytotoxicological study of PAMAM dendrimers - towards quantitative structure activity relationships. Toxicol. In Vitro. 2010a; 24:169-177.
62. Mukherjee SP, Lyng FM, Garcia A, Davoren M, Byrne HJ. Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells. Toxicol. Appl. Pharmacol. 2010b; 248: 259-268.
63. Naha PC, Davoren M, Lyng FM, Byrne HJ. Reactive oxygen species (ROS) induced cytokine production and cytotoxicity of PAMAM dendrimers in J774A.1 cells. Toxicol. Appl. Pharmacol. 2010; 246: 91-99. doi: 10.1016/j.taap.2010.04.014 PMID: 20420846
64. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood). 2008; 233(1): 4-11.
65. François H, Placier S, Flamant M, Tharaux PL, Chansel D, Dussaule JC, et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J. 2004; 18(7): 926-928. PMID: 15033924
66. Kabanov AV. Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv. Drug Deliv. 2006; 58:1597-1621.
67. Kuo JH, Liou MJ, Chiu HC. Evaluating the gene-expression profiles of HeLa cancer cells treated with activated and nonactivated poly(amidoamine) dendrimers, and their DNA complexes. Mol Pharm. 2010; 7: 805-814. doi: 10.1021/mp900303s PMID: 20394435
68. Jones CF, Campbell RA, Franks Z, Gibson CC, Thiagarajan G, Vieira-de-Abreu A, et al. Cationic PAMAM dendrimers disrupt key platelet functions. Mol. Pharm. 2012; 9(6): 1599-1611. doi: 10.1021/mp2006054 PMID: 22497592
69. Sun Y, Guo F, Zou Z, Li C, Hong X, Zhao Y, et al. Cationic nanoparticles directly bind angiotensin-converting enzyme 2 and induce acute lung injury in mice. Part Fibre Toxicol. 2015; 12(1): 4.
70. Benter IF, Yousif MH, Griffiths SM, Benboubetra M, Akhtar S. Epidermal growth factor receptortyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. Br J Pharmacol. 2005; 145: 829-836. PMID: 15852031